

AGARI CASE STUDY

Global 500 Health Care Company

Introduction

This case study of a Global 500 health care company is based on a January 2018 survey of Agari customers by TechValidate, a 3rd-party research service. The profiled company asked to have their name blinded to protect their confidentiality.



“We were able to identify and block advanced email attacks that SEGs missed by using Agari Enterprise Protect.”

Challenges

The profiled company evaluated and ultimately selected Agari Enterprise Protect to:

- Deploy advanced threat protection for email security
- Protect against business email compromise and executive spoofing attacks
- Protect against spear phishing attacks

Use Case

The company uses Cisco as their existing Secure Email Gateway and FireEye to provide Advanced Threat Protection for their email channel.

The company chose Agari Enterprise Protect to shield themselves from:

- Spear phishing
- Business email compromise/executive spoofing
- Spam

Results

The surveyed company achieved the following results with Agari Enterprise Protect:

- Prevented advanced email-based attacks that currently bypass existing security
- Prevented data breaches initiated via email
- Reduced costs of investigating suspicious messages

The company's rating of Agari's detection and prevention capabilities was as follows:

- Advanced email attacks: better than the competition
- Impostor based attacks: better than the competition
- Incident response & forensics: better than the competition

Company Profile

The company featured in this case study asked to have its name publicly blinded because publicly endorsing vendors is against their policies.

TechValidate stands behind the authenticity of this data.

Company Size:
Global 500

Industry:
Health Care

About Agari

Agari, a leading cybersecurity company, is trusted by leading Fortune 1000 companies to protect their enterprise, partners and customers from advanced email phishing attacks.

Learn More:

[Agari](#)

Source: TechValidate survey of a Global 500 Health Care Company

 Validated Published: Jan. 29, 2018 TVID: 639-4FF-FDA

Research by  TechValidate